| Literature DB >> 1657617 |
W Lesslauer1, H Tabuchi, R Gentz, M Brockhaus, E J Schlaeger, G Grau, P F Piguet, P Pointaire, P Vassalli, H Loetscher.
Abstract
The in vivo efficacy of human recombinant soluble tumor necrosis factor (TNF) receptor protein to prevent and to treat lipopolysaccharide (LPS)-induced lethal toxicity in D-galactosamine-treated mice was investigated. Chimeric proteins of the receptor extracellular domains fused to the hinge region of human IgG3 were expressed in myeloma cells (rsTNFR-h gamma 3). The fusion proteins had a disulfide-bonded dimeric structure. Upon intravenous injection, their serum concentration decreased relatively slowly after an initial phase of rapid elimination. D-galactosamine-sensitized mice were fully protected from the toxic effects of LPS, if the animal were pretreated with rsTNFR-h gamma 3 at 20 micrograms/animal. Partial protection was seen at significantly lower doses and when rsTNFR-h gamma 3 was given up to 3 h after LPS.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1657617 DOI： 10.1002/eji.1830211134
Source DB: PubMed Journal: Eur J Immunol ISSN： 0014-2980 Impact factor: 5.532